Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.50 |
| ▸ | FAP | Q12884 | 10/20 | 0.38 |
| ▸ | PREP | P48147 | 10/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.36 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21105170 | 1.00 | DPP4 (0.50) | DPP4FAPPREPCTSKDPP9 | |
| SCHEMBL17180405 | 1.00 | DPP4 (0.50) | DPP4FAPPREPCTSKDPP9 | |
| SCHEMBL2124054 | 0.86 | CTSK (0.41) | DPP4CTSKDPP9DPP8 | |
| SCHEMBL26782713 | 0.85 | HSD17B10 (0.36) | DPP4CTSK | |
| SCHEMBL5373165 | 0.81 | DPP4 (0.40) | DPP4FAPPREPDPP9DPP8 | |
| SCHEMBL23760630 | 0.80 | DPP4 (0.52) | DPP4FAPPREPCTSKDPP9 | |
| SCHEMBL21105037 | 0.80 | DPP4 (0.52) | DPP4FAPPREPCTSKDPP9 | |
| SCHEMBL22169492 | 0.80 | DPP4 (0.52) | DPP4FAPPREPCTSKDPP9 | |
| SCHEMBL15130380 | 0.79 | PREP (0.52) | DPP4FAPPREPDPP9DPP8 | |
| SCHEMBL15130381 | 0.79 | PREP (0.52) | DPP4FAPPREPDPP9DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025133915-A1 | COMPOUNDS WHICH BIND TO PNPLA3I148M AND THEIR USE TO TREAT LIVER DISEASES | NOVARTIS AG (CH) | 2025-06-26 | — | — | WO | disclosed |
| CN-115160204-B | Fibroblast activation protein inhibitor and preparation method and application thereof | 山东大学 | 2024-04-09 | — | — | CN | disclosed |
| CN-116583303-A | Tripterine conjugates and uses thereof | 瑞阳公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-111991570-B | FAP-alpha specific tumor diagnosis SPECT imaging agent | 北京大学 | 2021-05-18 | — | — | CN | disclosed |
| CN-111991570-A | FAP-alpha specific tumor diagnosis SPECT imaging agent | 北京大学 | 2020-11-27 | — | — | CN | disclosed |
| US-10112956-B2 | Heterocyclic compounds having cholesterol 24-hydroxylase activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-30 | — | — | US | disclosed |
| EP-2933247-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-08-29 | — | — | EP | disclosed |
| US-20170197983-A1 | HETEROCYCLIC COMPOUNDS HAVING CHOLESTEROL 24-HYDROXYLASE ACTIVITY | TAKEDA PHARMACEUTICALS CO (JP) | 2017-07-13 | — | — | US | disclosed |
| US-9643957-B2 | Heterocyclic compounds having cholesterol 24-hydroxylase activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-09 | — | — | US | disclosed |
| US-20150315209-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-05 | — | — | US | disclosed |
| EP-2933247-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10112956-B2 | Heterocyclic compounds having cholesterol 24-hydroxylase activity | CYP46A1, CYP27A1, NCEH1 | DPP4 603/4885FAP 1202/4885PREP 832/4885 |
| US-20170197983-A1 | HETEROCYCLIC COMPOUNDS HAVING CHOLESTEROL 24-HYDROXYLASE ACTIVITY | CYP46A1, CYP27A1, NCEH1 | DPP4 603/4885FAP 1202/4885PREP 832/4885 |
| US-20150315209-A1 | HETEROCYCLIC COMPOUND | HCN4, KCNH1, SCN4A | DPP4 431/4885FAP 2087/4885PREP 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.